Remove IPO Remove Medical Remove Trading
article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy.

M&A 64
article thumbnail

The Full Guide to Healthcare Private Equity, from Careers to Contradictions

Mergers and Inquisitions

The short answer to #1 is that healthcare private equity firms operate in specific verticals with stable-ish cash flows, such as healthcare services, nursing facilities, medical devices, equipment, and healthcare IT. Areas like healthcare services and medical devices are fairly generalist and follow standard accounting and valuation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value.

M&A 52
article thumbnail

24 venture capital firms you need to know about – Growth Business guide

Growth Business

Investment range: £50,000 – £3m Sectors: fintech, insurtech, regtech, digital health and medical technology, artificial intelligence and machine learning, consumer services, digital media, semiconductors and displays, cybersecurity, enterprise software, autonomous systems and human computer interfaces, novel materials and quantum technology.

Capital 52
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

Certain headwinds and other complicating factors, however, may have tamped down M&A activity in 2021, including: Antitrust regulators continuing to produce uncertainty, with the Federal Trade Commission announcing a number of key policy changes – the full impact of these policy changes on transactions remains to be seen.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

In the US, the Federal Trade Commission and the Department of Justice under the Biden administration have shifted their priorities and rhetoric in favor of tougher enforcement, with consolidation in the tech sector being one of their top targets.

M&A 52